Computational modeling of the pharmacokinetics and pharmacodynamics of selected xenobiotics
Date
2016
Authors
Zurlinden, Todd J., author
Reisfeld, Brad, advisor
Hays, Sean, committee member
Shipman, Patrick, committee member
Munsky, Brian, committee member
Journal Title
Journal ISSN
Volume Title
Abstract
The determination of important endpoints in toxicology and pharmacology continues to involve the acquisition of large amounts of data through resource-intensive experimental studies involving a large number of resources. Because of this, only a small fraction of chemicals in the environment and marketplace can reasonably be evaluated for safety, and many promising drug candidates must be eliminated from consideration based on inadequate evaluation. Promisingly, advances in biologically-based computational models are beginning to allow researchers to estimate these endpoints and make useful extrapolations using a limited set of experimental data. The work described in this dissertation examined how computational models can provide meaningful insight and quantitation of important pharmacological and toxicological endpoints related to toxicity and pharmacological efficacy. To this end, physiologically-based pharmacokinetic and pharmacodynamic models were developed and applied for several pharmaceutical agents and environmental toxicants to predict significant, and diverse, biological endpoints. First, physiologically-based modeling allowed for the evaluation of various dosing regimens of rifapentine, a drug that is showing great promise for the treatment of tuberculosis, by comparing lung-specific concentration predictions to experimentally-derived thresholds for antibacterial activity. Second, physiologically-based pharmacokinetic modeling, coupled with Bayesian inference, was used as part of a methodology to characterize genetic differences in acetaminophen pharmacokinetics and also to help clinicians predict an ingested dose of this drug under overdose conditions. Third, a methodology for using physiologically-based pharmacokinetic modeling to predict health-based cognitive endpoints was demonstrated for chronic exposure to chlorpyrifos, an organophosphorus insecticide. The environmental public health indicators derived from this work allowed for biomarkers of exposure to be used to predict neurobehavioral changes following long-term exposure to this chemical. Finally, computational modeling was used to develop a mechanistically-plausible pharmacodynamic model for hepatoprotective and pro-inflammatory events to relate trichloroethylene dosing conditions to observed pathologies associated with auto-immune hepatitis.
Description
Rights Access
Subject
biological modeling
pharmacodynamic modeling
Bayesian inference
physiologically-based pharmacokinetic modeling
computational pharmacology